Today's CAR T Options in Multiple Myeloma Care with Luciano Costa, MD, UAB
HealthTree Podcast for Multiple Myeloma
00:00
Advancements in CAR-T Therapy for Multiple Myeloma Patients
Exploring the latest FDA-approved drugs PECMA and CAR-VICTI for heavily relapsed multiple myeloma patients, highlighting their high response rates compared to older drugs. The discussion delves into the challenges of using CAR-T therapies in clinical settings, emphasizing the complexities of patient eligibility and timing constraints. Additionally, the chapter addresses the unpredictability of therapy responses, typical side effects like cytokine release syndrome and neurotoxicity, and the management of potential neurological side effects in cancer treatment.
Transcript
Play full episode
